According to Zhitong Finance App, Shiyao Group (01093.HK) announced that the Phase II clinical trial of injectable sirolimus (albumin binding type) developed independently by the Group to treat patients with progressive or symptomatic epithelioid hemangioendothelioma has officially started at the first center in China.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.